explore -WSS

explore

author：hotspot 2025-08-26 23:48:10 - browse：5

The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout Newsletter: The latest at Gilead, Catalent, and the NIH

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

NYU radiologists take on the challenge of expensive MRI machines

PhRMA lawsuit over Medicare drug price negotiation tossed

Why did Pfizer dish out millions for a Super Bowl ad?

How digital tools helped lower hypertension in marginalized patients

knowledge

explore

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PBM reforms clear House panel

The cancer drug shortage isn’t new — and neither are the solutions

Astellas still sees hope in its gene therapy after four deaths

In age of alternative facts, a scholarly course on calling out crap

How digital tools helped lower hypertension in marginalized patients

Drug repurposing or repositioning? The language matters

Vaccine advisory panel ACIP left half staffed by HHS

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

hotspot

Gain of function research would be limited under House proposal

What we’ve learned from the Aduhelm mess

Hospitals look to new technology to keep health care workers safe

Readout LOUD podcast: A CRISPR milestone, biotech mixology

David Sabatini, ex

Industry veterans launch new biotech VC with $310M

focus

leisure time

leisure time

hotspot